# FDA 483 - Matthew S. Bowdish, M.D., Clinical Investigator - October 27, 2014

Source: https://www.keypedia.com/records/483/matthew-s-bowdish-md-clinical-investigator/c1461949-e479-47e6-9244-d05270a8ffb4

> FDA 483 for Matthew S. Bowdish, M.D., Clinical Investigator on October 27, 2014. Product: drugs. Access full analysis and detailed observations.

---

## Details

- Record Type: 483
- Company Name: Matthew S. Bowdish, M.D., Clinical Investigator
- Inspection Date: 2014-10-27
- Product Type: drugs
- Office Name: Denver District Office
- Summary: Matthew S. Bowdish, M.D., Clinical Investigator, was inspected regarding investigational drug studies in Colorado Springs, CO. The inspection revealed significant deficiencies, including failures to report adverse events to the sponsor and IRB, and enrolling unqualified subjects. Additionally, the firm failed to maintain adequate and accurate case histories, indicating a lack of adherence to regulatory requirements for clinical investigations.

## Related Officers

- [investigator](https://www.keypedia.com/people/christine-i-shaw/480cb61e-f173-432d-b84a-c8b492192302)

Company: https://www.keypedia.com/companies/matthew-s-bowdish-md-clinical-investigator/c04ebef9-86c1-4b49-9d29-cd0f5b61d163

Office: https://www.keypedia.com/offices/denver-district-office/93b79063-390c-4759-af6c-5da7e388face